Weight management · Phase 1
Oral amycretin: first human study
What was tested?
Oral amycretin versus placebo in several early ascending-exposure cohorts. ↗
Registered primary question: The number of treatment-emergent adverse events, with follow-up windows of 22, 31 or 105 days depending on study part. ↗
What the reviewed report found
Journal year 2025 · Article summary reviewed 2026-09-15
Treatment-emergent adverse events were reported in 89 participants and were mild or moderate; gastrointestinal events were common.↗
Keep in context: The 144 participants were spread across different study parts. Weight-related outcomes were exploratory, and the parts did not all share the same treatment duration. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 144 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Sequential
- Eligible ages
- 18 Years to 55 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2025-06-15; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Oral amycretin: first-in-human study
- Design in the report
- A blinded randomized placebo-controlled phase 1 study contained several escalating-exposure parts.↗
- Participants in the report
- The study enrolled 144 adults with overweight or obesity across its parts.↗
- Limitations
- Safety was the primary endpoint; weight-related measures were exploratory. Small cohorts and short follow-up do not establish long-term clinical benefit or safety.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity ↗
Protocol identifier: NN9487-4830. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 660d4e938ebb5327ba29e76ad3f42f5f0bdfd7df6c2dd4bbbb62a1be6ab57cf2.
PMID 40550229
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 40550229. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 54e5149216ac86bce906130f2c186b95c201d99d222e6af2f785c610e72e3137.